Thymosin Alpha-1 30 mg peptide pen
The defined 28-residue immune peptide at thirty milligrams, licensed in dozens of countries as Zadaxin, supplied here as research material with the class’s best-documented sequence.
- ISO-certified laboratory
- COA per batch, ≥99% HPLC
- Discreet dispatch within 24 h
- Research use only
Defined sequence, deep dossier
Thymosin Alpha-1 is what the thymic-research tradition looks like when it resolves to a single molecule: 28 residues, N-terminally acetylated, with immune-function literature that includes genuine clinical use in several dozen countries under the name Zadaxin. The trials behind that use are registered on ClinicalTrials.gov.
Here it is research material with a research certificate, one identity, one mass, one purity trace, in exactly the way its extract cousin thymalin cannot be documented. For immune-axis research wanting a characterised tool, this is the shelf’s answer.
| Compound | Thymosin Alpha-1 |
| Content | 30 mg, pre-filled |
| Sequence | 28 residues, acetylated |
| Purity | ≥ 99% (HPLC) |
| Clinical history | Licensed abroad as Zadaxin |
| Related | Thymalin, the extract |
| Category | Research use only |
Clinical use elsewhere is context, not permission, the research-only line holds here as everywhere.
Before the Thymosin Alpha-1 30 mg peptide pen reaches the bench
Standard regimen; acetylation asks nothing extra of storage.
The honest record, read straight
Sorting the immune peptide’s real dossier from the claims it cannot carry.
The honest reading of Thymosin Alpha-1’s literature is that it carries more than almost anything near it, and still less than a headline wants. Its twenty-eight-residue, acetylated sequence has been examined in immune-function work and used clinically abroad, which is genuine signal, not folklore. What that record does not become is permission, or dosing guidance for people: it ships strictly for research, on the terms the research-use page spells out, and the clinical work elsewhere describes a licensed medicine in its own regulatory frame, not this cartridge.
Where the evidence stops deserves as much emphasis as where it runs. Much of the strongest data sits inside specific licensed indications under the Zadaxin name, and stretching those results to open-ended immune research is the leap the compound page declines to make for you. Treat the thirty-milligram pen as a well-characterised tool with a real but bounded dossier: strong enough to take seriously, narrow enough that sound work cites the actual studies, not the reputation grown around the sequence.
One batch, line by line
What the certificate for your exact lot should say, and what its identity line proves.
Reading the certificate for a thymosin alpha-1 pen is easier than for the extract preparation beside it, because one identity resolves cleanly. The mass-spectrometry figure must match the value predicted for the acetylated 28-residue chain; omit the N-terminal acetyl group from that prediction and the number belongs to a different molecule, so a certificate silent on acetylation documents the wrong thing. HPLC purity sits alongside at ninety-nine percent or better, and the two figures together characterise the material, not merely name it.
One check is worth the half-minute it takes: the batch identifier stamped on the pen must equal the one printed on the certificate in your inbox, not a sibling lot’s. Documentation lifted from an earlier batch is the usual shortcut elsewhere, listed among the warning signs on our page on doctored certificates, and it silently divorces the paper from the object in hand. Line the identifiers up, confirm the acetylated identity, and log both, so the certificate becomes evidence about this cartridge rather than a lot it never touched.
The immune shelf
The extract tradition it emerged from, and the anti-inflammatory fragment beside it.
The science behind Thymosin Alpha-1
Sequence, history and the extract contrast.
Questions about the Thymosin Alpha-1 30 mg peptide pen
For the immune shelf’s flagship.